Dublin, April 03, 2018 (GLOBE NEWSWIRE) -- The "Epiomic Epidemiology Series: Retinal Vein Occlusion Forecast in 18 Major Markets 2018-2028" report has been added to ResearchAndMarkets.com's offering.

Retinal vein occlusion (RVO) is a common vascular disorder of the retina and the second-most common cause of vision loss worldwide after diabetic retinopathy. Its classification and pathogenesis have not yet been fully established, and even though a range of therapeutic approaches to RVO are available, sequelae of the disorder may still lead to a significant degree of vision loss by various mechanisms.

This report provides the current prevalent population for RVO across 18 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the author's, RVO subtypes, several features of RVO patients, as well as the main comorbidities of the disease have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities of RVO include:

• Cardiovascular diseases (mainly hypertension)
• Diabetes mellitus
• Hypertension
• Glaucoma

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world-class sources that deliver the most up-to-date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Ability to quantify patient populations in global RVO market to target the development of future products, pricing strategies and launch plans.
• Further insight into the prevalence of the subdivided types of RVO and identification of patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Better understanding of the impact of specific co-morbid conditions on the prevalent population of RVO patients.
• Identification of RVO patient sub-populations that require treatment.
• Better understanding of the specific markets that have the largest number of RVO patients.

Key Topics Covered:

1. Introduction
2. Cause Of The Disease
3. Risk Factors & Prevention
4. Diagnosis Of The Disease
5. Variation By Geography/Ethnicity
6. Disease Prognosis & Clinical Course
7. Key Comorbid Conditions / Features Associated With The Disease
8. Methodology For Quantification Of Patient Numbers
9. Top-Line Prevalence For Retinal Vein Occlusion
10. Features Of Retinal Vein Occlusion Patients
11. Central Rvo
12. Branch Rvo
13. Abbreviations Used In The Report
14. Other Black Swan Services & Solutions
15. Reports & Publications
16. Online Epidemiology Databases
17. Online Pharmaceutical Pricing Database
18. References
19. Appendix
    

For more information about this report visit https://www.researchandmarkets.com/research/q8lfzh/retinal_vein?w=12

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Optical